1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 03/2007, NCT00719017
|
|
2.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LACE001, NCT00096408
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: CKTO-2006-04, ISRCTN14387080, CKTO-PORTEC-3, EU-20664, NCT00411138
|
|
4.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-002948-28, KKS-73-05, NCT00444093
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: SARC-GYN1, NCT00162721
|
|
6.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VRAM M-20070240, NCT00647569
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: EORTC-62072, EORTC 62072, EU-20887, NCT00753688, PALETTE, GSK-VEG110727, EUDRACT-2008-001307-33
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0249, GOG-0249, NCT00807768
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IP-CAT-AC-03, NCT00822809
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA163-196, 2008-007167-16, NCT00883116
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UHN REB 03-0298-C, NCT00188578
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID03-0047, NCT00508703
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UTHSC-MS-96205, NCI-V97-1356, NCT00003135
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04-247, NCT00129727
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UMN-2004LS021, UMN-WCC-38, NCT00258362
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: MMC-01-09-227, NCT00231868
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CFEM345ADE08, NCT00171808
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: HSC-MS-01-111, HSC-MS-01-111, NCT00178802
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 06US03IMP-852A [Cooley], MT2006-02, NCT00319748
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: KGOG2001, NCT00373620
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-062, 7713, PHL-062, NCT00478426
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2006-0211, NCT00392769
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2003-0823, NCT00388154
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-0229F, GOG-0229F, NCT00462826
|
|
25.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
